BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32339229)

  • 21. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
    Worst BC; van Tilburg CM; Balasubramanian GP; Fiesel P; Witt R; Freitag A; Boudalil M; Previti C; Wolf S; Schmidt S; Chotewutmontri S; Bewerunge-Hudler M; Schick M; Schlesner M; Hutter B; Taylor L; Borst T; Sutter C; Bartram CR; Milde T; Pfaff E; Kulozik AE; von Stackelberg A; Meisel R; Borkhardt A; Reinhardt D; Klusmann JH; Fleischhack G; Tippelt S; Dirksen U; Jürgens H; Kramm CM; von Bueren AO; Westermann F; Fischer M; Burkhardt B; Wößmann W; Nathrath M; Bielack SS; Frühwald MC; Fulda S; Klingebiel T; Koscielniak E; Schwab M; Tremmel R; Driever PH; Schulte JH; Brors B; von Deimling A; Lichter P; Eggert A; Capper D; Pfister SM; Jones DT; Witt O
    Eur J Cancer; 2016 Sep; 65():91-101. PubMed ID: 27479119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
    Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation and use of whole exome sequencing for metastatic solid cancer.
    Réda M; Richard C; Bertaut A; Niogret J; Collot T; Fumet JD; Blanc J; Truntzer C; Desmoulins I; Ladoire S; Hennequin A; Favier L; Bengrine L; Vincent J; Hervieu A; Dusserre JG; Lepage C; Foucher P; Borg C; Albuisson J; Arnould L; Nambot S; Faivre L; Boidot R; Ghiringhelli F
    EBioMedicine; 2020 Jan; 51():102624. PubMed ID: 31923800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and clinical application of an integrative genomic approach to personalized cancer therapy.
    Uzilov AV; Ding W; Fink MY; Antipin Y; Brohl AS; Davis C; Lau CY; Pandya C; Shah H; Kasai Y; Powell J; Micchelli M; Castellanos R; Zhang Z; Linderman M; Kinoshita Y; Zweig M; Raustad K; Cheung K; Castillo D; Wooten M; Bourzgui I; Newman LC; Deikus G; Mathew B; Zhu J; Glicksberg BS; Moe AS; Liao J; Edelmann L; Dudley JT; Maki RG; Kasarskis A; Holcombe RF; Mahajan M; Hao K; Reva B; Longtine J; Starcevic D; Sebra R; Donovan MJ; Li S; Schadt EE; Chen R
    Genome Med; 2016 Jun; 8(1):62. PubMed ID: 27245685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
    Groisberg R; Hong DS; Roszik J; Janku F; Tsimberidou AM; Javle M; Meric-Bernstam F; Subbiah V
    Mol Cancer Ther; 2018 Jul; 17(7):1595-1601. PubMed ID: 29654067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric oncology enters an era of precision medicine.
    Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
    Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized oncology through integrative high-throughput sequencing: a pilot study.
    Roychowdhury S; Iyer MK; Robinson DR; Lonigro RJ; Wu YM; Cao X; Kalyana-Sundaram S; Sam L; Balbin OA; Quist MJ; Barrette T; Everett J; Siddiqui J; Kunju LP; Navone N; Araujo JC; Troncoso P; Logothetis CJ; Innis JW; Smith DC; Lao CD; Kim SY; Roberts JS; Gruber SB; Pienta KJ; Talpaz M; Chinnaiyan AM
    Sci Transl Med; 2011 Nov; 3(111):111ra121. PubMed ID: 22133722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of Exceptional or Super Responders to Cancer Drugs.
    Prasad V; Vandross A
    Mayo Clin Proc; 2015 Dec; 90(12):1639-49. PubMed ID: 26546106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
    George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
    Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
    Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
    J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM.
    Ma J; Setton J; Morris L; Albornoz PB; Barker C; Lok BH; Sherman E; Katabi N; Beal K; Ganly I; Powell SN; Lee N; Chan TA; Riaz N
    Oncotarget; 2017 Feb; 8(6):10312-10323. PubMed ID: 28055970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
    Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
    Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer.
    Wong M; Mayoh C; Lau LMS; Khuong-Quang DA; Pinese M; Kumar A; Barahona P; Wilkie EE; Sullivan P; Bowen-James R; Syed M; Martincorena I; Abascal F; Sherstyuk A; Bolanos NA; Baber J; Priestley P; Dolman MEM; Fleuren EDG; Gauthier ME; Mould EVA; Gayevskiy V; Gifford AJ; Grebert-Wade D; Strong PA; Manouvrier E; Warby M; Thomas DM; Kirk J; Tucker K; O'Brien T; Alvaro F; McCowage GB; Dalla-Pozza L; Gottardo NG; Tapp H; Wood P; Khaw SL; Hansford JR; Moore AS; Norris MD; Trahair TN; Lock RB; Tyrrell V; Haber M; Marshall GM; Ziegler DS; Ekert PG; Cowley MJ
    Nat Med; 2020 Nov; 26(11):1742-1753. PubMed ID: 33020650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
    Flaherty KT; Gray R; Chen A; Li S; Patton D; Hamilton SR; Williams PM; Mitchell EP; Iafrate AJ; Sklar J; Harris LN; McShane LM; Rubinstein LV; Sims DJ; Routbort M; Coffey B; Fu T; Zwiebel JA; Little RF; Marinucci D; Catalano R; Magnan R; Kibbe W; Weil C; Tricoli JV; Alexander B; Kumar S; Schwartz GK; Meric-Bernstam F; Lih CJ; McCaskill-Stevens W; Caimi P; Takebe N; Datta V; Arteaga CL; Abrams JS; Comis R; O'Dwyer PJ; Conley BA;
    J Natl Cancer Inst; 2020 Oct; 112(10):1021-1029. PubMed ID: 31922567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perspectives on research activity in the USA on Cancer Precision Medicine.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized genomic analyses for cancer mutation discovery and interpretation.
    Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
    Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.
    Kato S; Kurasaki K; Ikeda S; Kurzrock R
    Oncologist; 2018 Feb; 23(2):171-178. PubMed ID: 29038235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
    Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
    J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.
    Mueller S; Jain P; Liang WS; Kilburn L; Kline C; Gupta N; Panditharatna E; Magge SN; Zhang B; Zhu Y; Crawford JR; Banerjee A; Nazemi K; Packer RJ; Petritsch CK; Truffaux N; Roos A; Nasser S; Phillips JJ; Solomon D; Molinaro A; Waanders AJ; Byron SA; Berens ME; Kuhn J; Nazarian J; Prados M; Resnick AC
    Int J Cancer; 2019 Oct; 145(7):1889-1901. PubMed ID: 30861105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.
    Oberg JA; Glade Bender JL; Sulis ML; Pendrick D; Sireci AN; Hsiao SJ; Turk AT; Dela Cruz FS; Hibshoosh H; Remotti H; Zylber RJ; Pang J; Diolaiti D; Koval C; Andrews SJ; Garvin JH; Yamashiro DJ; Chung WK; Emerson SG; Nagy PL; Mansukhani MM; Kung AL
    Genome Med; 2016 Dec; 8(1):133. PubMed ID: 28007021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.